Why Is There a Shortage of Adderall? The Full Explanation (2026 Update)

The Adderall shortage exists because of a simultaneous collision of four forces: a massive, sustained surge in demand driven by pandemic-era telehealth prescribing expansion; DEA-enforced production quotas that cap how much amphetamine manufacturers can produce annually; fragile generic manufacturing infrastructure where multiple companies have exited the market or discontinued formulations; and upstream supply chain dependencies on active pharmaceutical ingredient (API) suppliers that were disrupted by COVID-19. The shortage began in October 2022, has now persisted for nearly four years, and as of mid-2026 remains officially unresolved — though modestly improved following DEA quota increases in late 2025 and early 2026.

Table of Contents

Introduction

When the FDA officially announced a national Adderall shortage in October 2022, it cited “ongoing intermittent manufacturing delays” at Teva Pharmaceuticals — framing it as a production blip. Almost four years later, that framing has been thoroughly dismantled. The Adderall shortage is not a blip. It is a structural failure at the intersection of drug regulation, market economics, manufacturing capacity, and an unprecedented explosion in ADHD diagnosis — and understanding why it exists requires understanding each of those dimensions.

This article explains every contributing cause in full, traces the timeline of how the shortage developed and why it has persisted, documents where the situation stands as of mid-2026, and gives patients and providers the honest picture of when — if ever — a resolution is likely.

The Timeline: How the Shortage Developed

Pre-2022: A Decade of Rising Demand

The Adderall shortage did not begin in 2022 — it was a decade in the making:

Adderall dispensing had been increasing consistently for more than a decade before the 2022 announcement
In 2021 alone, dispensed Adderall prescriptions reached 41.4 million, a 10.4% increase from 2020
This growth followed a decade of similar year-on-year increases — manufacturers were already running tight

2020–2022: The Telehealth Catalyst

The COVID-19 pandemic created the conditions for a sudden demand acceleration that the supply chain could not absorb:

In March 2020, the DEA temporarily waived the Ryan Haight Act requirement for in-person evaluation before prescribing controlled substances, enabling telehealth ADHD prescribing at scale
Direct-to-consumer telehealth platforms — some specifically built to prescribe Adderall rapidly — emerged and grew rapidly
Trilliant Health data shows that the emergence of these digital mental health platforms “enabled significant increases in prescribing, particularly for the Millennial generation”
Between 2020 and 2021, there was a 15% increase in Adderall prescriptions for adults aged 22–24 specifically — a cohort newly reached by telehealth ADHD services
By mid-2022, prescriptions were at an all-time high even as manufacturing was beginning to strain

October 2022: The FDA Announcement

October 12, 2022: the FDA officially declared a national Adderall shortage, citing manufacturing delays at Teva
Teva, the world’s largest Adderall supplier, had experienced a labour shortage at its manufacturing facilities, causing production to fall behind
Other manufacturers were also reporting backorders — not because their own plants were failing, but because the demand spike had exceeded collective production capacity across the market

2023: Demand Outpaces Manufacturing Recovery

Even after Teva’s labour issues were resolved, the shortage deepened:

The FDA acknowledged that by early 2023, the manufacturing delays had been resolved— but the shortage continued because demand now structurally exceeded supply
Jim McKinney of the FDA told CNN: “The current shortage is now driven by demand”
Multiple manufacturers began exiting the generic Adderall market entirely — finding the economics of a tightly quota-constrained, low-margin generic drug unattractive
The DEA estimated a one billion dose shortfall in both 2022 and 2023
Doctors began prescribing substitute ADHD medications (Vyvanse, Ritalin, Concerta) — causing cascade shortages of those alternatives
The shortage entered its second year with, as NPR reported, “no end in sight”

2024–2025: Structural Shortage Deepens

Generic manufacturers Mylan and Zydus discontinued their amphetamine mixed salt formulations entirely — reducing the number of manufacturers producing generic Adderall and concentrating remaining supply
Multiple children made the transition to alternative medications as paediatric prescribers could not reliably source Adderall
The DEA raised d-amphetamine production quotas in October 2025 by approximately 25% — the first increase since 2021 — from 21.2 million grams to 26.5 million grams
Lisdexamfetamine (Vyvanse) quotas were raised by approximately 22%
Methylphenidate quotas were raised by approximately 9%
Despite these increases, manufacturers reported recovery dates as TBD

2026: Improving But Unresolved

As of mid-2026, the FDA continues to list multiple amphetamine mixed salt formulations — including IR and XR versions of Adderall — on its Drug Shortages Database
The DEA increased 2026 Aggregate Production Quotas (APQs) for d,l-amphetamine by an additional 14% above the originally proposed level following over 5,000 public comments
The shortage is described as “improving but not resolved”
Some manufacturers have recovery dates indicating limited availability or back orders continuing through 2026

The Six Root Causes Explained

Cause 1 — The DEA Quota System

The most structurally significant and most debated cause of the Adderall shortage is the DEA’s Aggregate Production Quota (APQ) system:

How it works:Every year, the DEA sets a national production ceiling for Schedule II controlled substances — including amphetamines. This ceiling determines the total amount of active pharmaceutical ingredient (API) — in Adderall’s case, d,l-amphetamine — that all US manufacturers are collectively allowed to produce. Individual manufacturers apply to the DEA for a share of this total quota.

Why it creates shortages:

The quota system is designed to prevent diversion and illicit use by ensuring no more of the drug is produced than necessary for legitimate medical need
But accurately forecasting medical need a year in advance is inherently imprecise — particularly when demand is rising rapidly
When actual demand exceeds the quota ceiling, manufacturers cannot simply increase production — they need DEA approval, and the DEA has historically been slow to respond to demand spikes
ADDitude Magazine noted: “Thanks to production caps put in place by the Drug Enforcement Administration, the ADHD medication shortage will continue — with no end in sight”

The DEA’s counterpoint:The DEA has consistently stated that manufacturers have not used their full allotted quotas in recent years, and that the shortage is therefore not its fault:

“The majority of manufacturers contacted by DEA and/or FDA have responded that they currently have sufficient quota to meet their contracted production quantities”
In 2020, 2021, and 2022, US manufacturers did not use the total allotted amphetamine supply, according to the Federal Register
As one drug information expert noted: “A lot of the companies tell us that the reason they can’t have full availability is because of DEA quotas. But DEA says that the companies haven’t used all of their quota and they’re not going to increase it”

The truth is somewhere in the middle:Individual manufacturers may have unused quota while collectively the market is still short — because quota is not transferable between manufacturers. A manufacturer that has used its quota cannot borrow from one that has unused capacity. This structural rigidity means total quota can be technically “sufficient” while actual supply is still inadequate.

Cause 2 — The Telehealth Prescribing Explosion

The pandemic-era relaxation of controlled substance prescribing rules created a step-change increase in Adderall demand that the supply chain was not prepared for:

The DEA’s 2020 waiver removed the in-person evaluation requirement — allowing telehealth platforms to prescribe Adderall after a video consultation
Direct-to-consumer telehealth ADHD platforms emerged specifically to serve this demand — some with aggressive marketing and streamlined prescribing
Between 2020 and 2021, adult prescriptions grew by 15% in the 22–24 age bracket — a group with historically low rates of ADHD diagnosis now reached by digital services
Dispensed Adderall prescriptions hit 41.4 million in 2021, up 10.4% from 2020 — a single-year increase roughly equal to several years of prior organic growth combined
A CDC report confirmed that stimulant prescriptions surged during the pandemic, “especially among adults”
Trilliant Health concluded: “The emergence of digital mental health platforms enabled significant increases in prescribing, particularly for the Millennial generation”

Why this matters for the shortage:Manufacturers, DEA quota setters, and wholesalers calibrate their systems to historical demand trajectories. A sudden 10–15% single-year increase in demand — on top of a decade of existing growth — cannot be absorbed by a system with tight regulatory ceilings and limited manufacturing headroom. The telehealth prescribing surge effectively broke the supply chain’s forecasting model.

Cause 3 — Generic Market Economics and Manufacturer Exits

The economics of generic Adderall manufacturing have driven multiple companies to exit the market entirely — reducing the supplier base at exactly the moment demand is surging:

Why generic Adderall is a poor business:

Generic Adderall is a low-margin product — it is an old, off-patent drug in a saturated generic market
Manufacturing it requires a DEA Schedule II licence — expensive to obtain and maintain
Production is subject to strict DEA quota constraints — manufacturers cannot scale up quickly to meet demand spikes
When a manufacturer encounters a production problem (equipment failure, ingredient delay), it cannot compensate by simply buying more API — it is quota-limited
Profitability depends on consistently operating at or near full quota — any disruption hits margins hard

The result: Several generic Adderall manufacturers have concluded that the regulatory burden, quota constraints, and thin margins make the product commercially unviable:

Mylan — discontinued amphetamine mixed salt IR formulation
Zydus — discontinued amphetamine mixed salt IR formulation
Other smaller manufacturers have exited or paused production

As a Johns Hopkins health policy expert explained: “This is not a very expensive drug. And sometimes manufacturers are not paid enough, and so they may opt to exit the market”. Fewer manufacturers means less total production capacity, less supply redundancy when one manufacturer encounters problems, and higher concentration risk.

Cause 4 — Supply Chain Fragility and API Dependencies

Even manufacturers that want to produce more Adderall face upstream constraints they cannot control:

Active Pharmaceutical Ingredient (API) sourcing:

The amphetamine API used in Adderall — d,l-amphetamine — is manufactured by a small number of global suppliers, many based in Asia
COVID-19 disrupted global pharmaceutical supply chains, including API production and logistics
Several Adderall generic manufacturers cited “active ingredient delays” as a cause of their shortage listing — meaning they had the quota and the manufacturing capacity, but not the raw material

Three-wholesaler bottleneck:

More than 90% of all US drug transactions flow through just three large wholesalers — AmerisourceBergen, Cardinal Health, and McKesson
Manufacturers calibrate production to the purchase orders placed by these three wholesalers
This creates a rigid, centrally-controlled distribution system with little capacity to respond to sudden demand shifts at the pharmacy level
When a shortage hits, all pharmacies drawing from the same three wholesalers experience it simultaneously — which is why calling every CVS in your area is often futile

Limited excess manufacturing capacity:

Pharmaceutical manufacturers do not maintain large idle manufacturing capacity in reserve
Expanding production requires FDA approval if a different facility is to be used
Retooling or adding capacity takes months to years

Cause 5 — Rising ADHD Diagnosis Rates

The surge in demand is not solely attributable to telehealth prescribing practices — ADHD diagnosis rates themselves have risen substantially:

Pandemic conditions — remote work, remote school, reduced external structure — caused many adults with undiagnosed ADHD to recognise their symptoms for the first time
Increased cultural awareness of ADHD — driven by social media, advocacy communities, and public health education — reduced stigma and increased help-seeking
The COVID-19 pandemic itself may have genuinely worsened ADHD symptom burden for people who previously coped adequately with their condition in structured environments
As Klarity Health notes: “ADHD diagnoses rose sharply during and after the pandemic, driven in part by expanded telehealth access”

This represents a genuine unmet need, not simply overconsumption — making the shortage a public health problem as much as a regulatory or economic one.

Cause 6 — The Cascade Effect on Alternative Medications

The Adderall shortage has created a cascade shortage affecting ADHD medications that would otherwise serve as substitutes:

As Adderall became unavailable, prescribers switched patients to Vyvanse, Ritalin, Concerta, and Strattera — increasing demand for those medications beyond their normal supply baselines
Michigan Medicine research published in January 2025 found the Adderall shortage was associated with increased use of alternative ADHD medications in children — placing those alternatives under pressure
This cascade effect means that solving the Adderall shortage alone does not fully resolve access issues — the entire ADHD medication market has been destabilised

The DEA Quota Debate: Who Is Really to Blame?

The most contentious issue in the Adderall shortage is the mutual blame between manufacturers and the DEA:

The manufacturers’ position:

Manufacturers cannot produce more than their individual quota allocations allow — even if they have the capacity
When market demand exceeds the collective quota ceiling, no manufacturer can unilaterally solve it
Teva representatives suggested the DEA quota system is a primary contributor to the ongoing shortage

The DEA’s position:

Manufacturers did not use their full allotted quotas in 2020, 2021, and 2022 — so the quota is not the constraining factor
The shortage is a demand problem, not a supply ceiling problem
Total quota capacity was deemed adequate for legitimate medical need

The independent expert view:Drug shortage researchers and clinical pharmacists describe the reality as more nuanced than either party acknowledges:

Unused quota at one manufacturer does not benefit another manufacturer — quotas are not transferable
A manufacturer with unused quota may have strategic business reasons (capacity, margin, ingredient access) for not using it — the quota is a ceiling, not a target
The FDA cannot compel manufacturers to explain why they are not producing at full quota — there is no legal mechanism to force disclosure
As one expert put it: “A lot of companies are secretive about the details, and it’s frustrating that the FDA can’t force the companies to explain what’s causing a shortage”
The true picture involves both quota structure and manufacturer decisions interacting in ways that are opaque to regulators and the public alike

What Has Been Done and Why It Hasn’t Fixed It

DEA Quota Increases (2025–2026)

The most concrete regulatory response to the shortage has been the DEA’s quota increases:

October 2, 2025: DEA increased the 2025 APQ for d-amphetamine from 21.2 million grams to 26.5 million grams — a ~25% increase, the first since 2021
Lisdexamfetamine quota increased by approximately 22%
Methylphenidate quota increased by approximately 9%
Early 2026: DEA finalised 2026 APQs with an additional 14% increase above the originally proposed level for d,l-amphetamine, following 5,000+ public comments

Why it hasn’t fully resolved the shortage:Increasing the quota ceiling does not automatically translate to increased production:

Manufacturers still need to source API, retool production schedules, and navigate their own supply chain constraints
With Mylan and Zydus having discontinued their formulations, the increased quota is distributed among a smaller remaining manufacturer base
Manufacturing ramp-up takes months — quota increases take time to show up as pharmacy-level stock
The shortage has improved overall but remains officially unresolved as of mid-2026

The Surveillance System Gap

A deeper systemic problem identified by researchers is the absence of a real-time demand surveillance system:

As the Johns Hopkins expert explained to NPR: “Today, we’re very attuned. We have a good surveillance system for problems that happen on the manufacturer side. But when it’s the case of an increased demand, especially a sudden one and a fast-growing one, then we don’t really have a good surveillance system”. Without early warning of demand surges, the quota-setting process will always lag behind actual market need.

Will the Adderall Shortage End? The Honest Forecast

As of mid-2026, the shortage is improving but has no confirmed end date:

The FDA continues to list multiple amphetamine mixed salt formulations on its Drug Shortages Database
DEA quota increases in 2025–2026 are expected to gradually increase supply
Some manufacturers have provided recovery dates extending into 2026
But with Mylan and Zydus having left the market permanently, the supplier base remains structurally smaller than before the shortage began
As one independent expert summarised: “The shortage will end when supply meets demand — there’s no clear timeline”

The structural risk going forward:Even if the current shortage resolves, the conditions that created it — rising ADHD diagnosis rates, telehealth prescribing expansion, manufacturer market exits, API dependency, and a quota system that lags demand — remain in place. Without systemic regulatory reform, the Adderall market will remain vulnerable to future shortages.

What Patients Can Do Right Now

Given the shortage’s ongoing nature, practical patient strategies remain essential:

Use Medfinder (medfinder.com) to locate real-time stock near you before calling pharmacies individually
Try independent pharmacies and Costco — more consistently stocked than major chains
Ask your prescriber about Vyvanse — lisdexamfetamine (Vyvanse) has different shortage dynamics and is often more available; the DEA’s 22% quota increase for lisdexamfetamine in 2025 has improved its supply
Ask for post-dated 90-day prescriptions — having three 30-day prescriptions in hand at once gives you more flexibility in finding stock
Discuss manufacturer preference with your pharmacist — Teva continues to manufacture Adderall and may have better availability than other generic manufacturers at specific pharmacies
Time refills early — shortage-related delays mean last-minute refills are high-risk; begin the process 1–2 weeks before you run out

FAQ — Why Is There a Shortage of Adderall?

Why is there an Adderall shortage?The Adderall shortage is caused by a convergence of forces: an unprecedented demand surge driven by pandemic-era telehealth prescribing; DEA production quota ceilings that cap how much manufacturers can produce; multiple generic manufacturers exiting the market; API supply chain disruptions; and a distribution system concentrated through just three wholesalers with limited flexibility.

Is the Adderall shortage still happening in 2026?Yes — as of mid-2026, the FDA continues to list multiple amphetamine mixed salt formulations on its active Drug Shortages Database. The shortage is described as improving but unresolved, with DEA quota increases in late 2025 and early 2026 gradually increasing supply.

Did the DEA cause the Adderall shortage?Partly — the DEA’s quota system limits manufacturer production and is slow to respond to demand spikes. However, the DEA contends manufacturers did not use their full allotted quotas, and independent experts note the truth is more complex: quota structure, manufacturer market exits, API availability, and demand forecasting failures all contributed.

Did telehealth cause the Adderall shortage?Telehealth was a major accelerating factor — pandemic-era DEA waivers enabled a rapid expansion of Adderall prescribing through digital health platforms, generating a demand surge the supply chain was not calibrated for. It was not the sole cause — underlying ADHD diagnosis trends, quota constraints, and manufacturing fragility all predate telehealth expansion.

Why can’t manufacturers just make more Adderall?They are legally prohibited from doing so beyond their DEA-allocated quota. Even with excess manufacturing capacity, a manufacturer cannot produce more amphetamine than its individual APQ allows without DEA authorisation. Additionally, they require a consistent API supply, sufficient manufacturing capacity, and the commercial incentive to produce a low-margin controlled substance in a complex regulatory environment.

When will the Adderall shortage end?There is no confirmed end date. DEA quota increases in 2025–2026 are expected to gradually improve supply, but the FDA has not issued a resolution notice and multiple manufacturers continue to report limited availability or back orders into 2026. The structural factors — rising demand, tight quotas, reduced manufacturer base — mean the shortage’s full resolution depends on systemic changes not yet implemented.

What is the best alternative to Adderall during the shortage?Vyvanse (lisdexamfetamine) — same active compound, different manufacturing pathway, and subject to a 22% DEA quota increase in 2025 that has improved its availability. Dextroamphetamine (Dexedrine) is another pharmacologically equivalent option. Methylphenidate-based medications (Ritalin, Concerta) represent a different drug class but are effective for ADHD management and had their quota increased in 2025 as well. Discuss any switch with your prescriber.

The Bottom Line

The Adderall shortage is the product of a perfect storm: a decade of growing ADHD demand meeting a pandemic-era prescribing explosion, crashing into a regulatory quota system poorly equipped to respond to sudden demand surges, in a market where low margins have driven multiple manufacturers to exit entirely, with upstream supply chains that were disrupted by COVID-19 and never fully recovered. DEA quota increases in late 2025 and early 2026 represent meaningful regulatory progress — the first quota increases since 2021, totalling roughly 25% for d-amphetamine. But with the manufacturer base permanently smaller and a billion-dose annual shortfall to close, the improvement is gradual rather than definitive. As of mid-2026, the shortage is improving but not over — and patients navigating it need a combination of proactive pharmacy strategy, openness to clinically equivalent alternatives, and the knowledge that the shortage reflects a systemic failure of drug market regulation rather than a scarcity of clinical need.

Why is there a shortage of Adderall Hobart
Why is there a shortage of Adderall Devonport
Why is there a shortage of Adderall Launceston
Why is there a shortage of Adderall Tasmania
Why is there a shortage of Adderall Victoria
Why is there a shortage of Adderall Queensland
Why is there a shortage of Adderall Canberra
Why is there a shortage of Adderall Australian Capital Territory
Why is there a shortage of Adderall South Australia
Why is there a shortage of Adderall New South Wales
Why is there a shortage of Adderall Darwin
Why is there a shortage of Adderall Ghan
Why is there a shortage of Adderall Northern Territory
Why is there a shortage of Adderall Australia
Why is there a shortage of Adderall Austria
Why is there a shortage of Adderall Germany
Why is there a shortage of Adderall United Kingdom
Why is there a shortage of Adderall Sweden
Why is there a shortage of Adderall Denmark
Why is there a shortage of Adderall Norway
Why is there a shortage of Adderall Finland
Why is there a shortage of Adderall Iceland
Why is there a shortage of Adderall Netherlands
Why is there a shortage of Adderall Spain
Why is there a shortage of Adderall Ireland
Why is there a shortage of Adderall Switzerland